Aridis Pharmaceuticals (NASDAQ:ARDS) issued its earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.27, Bloomberg Earnings reports.

Shares of Aridis Pharmaceuticals stock opened at $6.90 on Friday. The stock has a fifty day simple moving average of $6.92 and a 200 day simple moving average of $6.70. Aridis Pharmaceuticals has a 12-month low of $3.80 and a 12-month high of $12.40. The company has a market capitalization of $67.82 million, a P/E ratio of -2.12 and a beta of 0.07.

ARDS has been the topic of a number of research reports. Zacks Investment Research raised Aridis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 15th. Maxim Group reaffirmed a “buy” rating and set a $17.00 target price on shares of Aridis Pharmaceuticals in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price target (up previously from $7.00) on shares of Aridis Pharmaceuticals in a report on Friday, May 15th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $15.29.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Read More: Average Daily Trade Volume – ADTV

Earnings History for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.